144 related articles for article (PubMed ID: 1558800)
1. Patterns of survival in patients with advanced Hodgkin's disease (HD) treated in a single centre over 20 years.
Oza AM; Ganesan TS; Dorreen M; Johnson PW; Waxman J; Gregory W; Lim J; Wright J; Dadiotis L; Barbounis V
Br J Cancer; 1992 Mar; 65(3):429-37. PubMed ID: 1558800
[TBL] [Abstract][Full Text] [Related]
2. Management of stage II Hodgkin's disease: 15 years experience at St. Bartholomew's Hospital.
Ganesan TS; Oza A; Perry N; D'Ardenne J; Arnott S; Stansfeld AG; Shand WS; Wrigley PF; Lister TA
Ann Oncol; 1992 May; 3(5):349-56. PubMed ID: 1377487
[TBL] [Abstract][Full Text] [Related]
3. The management of stage II supradiaphragmatic Hodgkin's disease at St. Bartholomew's Hospital. A retrospective review of 114 previously untreated patients over 14 years.
Dorreen MS; Wrigley PF; Laidlow JM; Plowman PN; Neudachin L; Tucker AK; Malpas JS; Stansfeld AG; Faux MM; Jones AE
Cancer; 1984 Dec; 54(12):2882-8. PubMed ID: 6548658
[TBL] [Abstract][Full Text] [Related]
4. A randomised study of adjuvant MVPP chemotherapy after mantle radiotherapy in pathologically staged IA-IIB Hodgkin's disease: 10-year follow-up.
Anderson H; Crowther D; Deakin DP; Ryder WD; Radford JA
Ann Oncol; 1991 Feb; 2 Suppl 2():49-54. PubMed ID: 2049321
[TBL] [Abstract][Full Text] [Related]
5. MVPP chemotherapy regimen for advanced Hodgkin's disease.
Sutcliffe SB; Wrigley PF; Peto J; Lister TA; Stansfeld AG; Whitehouse JM; Crowther D; Malpas JS
Br Med J; 1978 Mar; 1(6114):679-83. PubMed ID: 630293
[TBL] [Abstract][Full Text] [Related]
6. Mechlorethamine, vinblastine, procarbazine and prednisolone (MVPP) for advanced Hodgkin's disease.
Harding MJ; McNulty LJ; Paul J; Lee F; Brown A; Soukop M
Eur J Cancer; 1991; 27(8):1002-6. PubMed ID: 1832882
[TBL] [Abstract][Full Text] [Related]
7. Patterns of survival in patients with Hodgkin's disease: long follow up in a single centre.
Oza AM; Ganesan TS; Leahy M; Gregory W; Lim J; Dadiotis L; Barbounis V; Jones AE; Amess J; Stansfeld AG
Ann Oncol; 1993 May; 4(5):385-92. PubMed ID: 8353073
[TBL] [Abstract][Full Text] [Related]
8. OPEC chemotherapy (vincristine, prednisolone, etoposide and chlorambucil) for refractory and recurrent Hodgkin's disease.
Barnett MJ; Man AM; Richards MA; Waxman JH; Wrigley PF; Lister TA
Hematol Oncol; 1987; 5(2):79-82. PubMed ID: 3596472
[TBL] [Abstract][Full Text] [Related]
9. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
10. MVPP chemotherapy combined with radiotherapy in the treatment of Hodgkin's disease in children: long-term results.
Armata J; Borkowski W; Depowska T
Am J Pediatr Hematol Oncol; 1984; 6(4):462-5. PubMed ID: 6549497
[TBL] [Abstract][Full Text] [Related]
11. ChlVPP combination chemotherapy for Hodgkin's disease: long-term results.
Selby P; Patel P; Milan S; Meldrum M; Mansi J; Mbidde E; Brada M; Perren T; Forgeson G; Gore M
Br J Cancer; 1990 Aug; 62(2):279-85. PubMed ID: 2386744
[TBL] [Abstract][Full Text] [Related]
12. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
13. Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data.
Prosnitz LR; Farber LR; Kapp DS; Scott J; Bertino JR; Fischer JJ; Cadman EC
J Clin Oncol; 1988 Apr; 6(4):603-12. PubMed ID: 2451712
[TBL] [Abstract][Full Text] [Related]
14. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.
Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L
J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381
[TBL] [Abstract][Full Text] [Related]
15. British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results.
Hancock BW; Vaughan Hudson G; Vaughan Hudson B; Haybittle JL; Bennett MH; MacLennan KA; Jelliffe AM
Br J Cancer; 1991 Apr; 63(4):579-82. PubMed ID: 2021542
[TBL] [Abstract][Full Text] [Related]
16. Factors affecting remission and survival in patients with advanced Hodgkin's disease treated with MVPP.
Wagstaff J; Steward W; Jones M; Deakin D; Todd I; Wilkinson P; Scarffe JH; Harris M; Crowther D
Hematol Oncol; 1986; 4(2):135-47. PubMed ID: 2427429
[TBL] [Abstract][Full Text] [Related]
17. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study.
Salloum E; Doria R; Farber LR; Roberts KB; Cooper DL
Cancer J Sci Am; 1995; 1(4):267-73. PubMed ID: 9166487
[TBL] [Abstract][Full Text] [Related]
18. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM
Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222
[TBL] [Abstract][Full Text] [Related]
19. The treatment of stage IIIA Hodgkin's disease.
Lister TA; Dorreen MS; Faux M; Jones AE; Wrigley PF
J Clin Oncol; 1983 Dec; 1(12):745-9. PubMed ID: 6689424
[TBL] [Abstract][Full Text] [Related]
20. Hodgkin's disease in children. A ten-year experience in South Africa.
Jacobs P; King HS; Karabus C; Hartley P; Werner D
Cancer; 1984 Jan; 53(2):210-3. PubMed ID: 6546299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
